The susceptibility of low-density lipoprotein to in vitro oxidation is increased in hypercholesterolemic patients.
It has been suggested that the oxidative modification of low-density lipoprotein (LDL) plays a major role in atherogenesis. We evaluated the oxidative resistance to copper-induced oxidative changes of LDL derived from patients affected by type IIa hyperlipoproteinemia compared with healthy subjects and faced the question of the importance of the antioxidants and polyunsaturated fatty acids (PUFAs) contained in LDL in determining its variability. LDL isolated from the plasmas of 25 subjects affected by familial hypercholesterolemia and 15 control subjects was oxidatively modified with Cu2+ in vitro, and the differences in LDL susceptibilities (lag and propagation phases) to lipid peroxidation were studied by measuring the changes in fluorescence intensity. LDL alpha-tocopherol and PUFAs were also measured. The lag phase was significantly lower and the propagation phase significantly higher in the type IIa patients than in control subjects (p < 0.01). The linoleic and arachidonic acids, expressed as percentage of total LDL fatty acids, were significantly higher in type IIa patients than in the control subjects (p < 0.01). There was a positive significant correlation between the LDL cholesterol and the linoleic and arachidonic acids as percentage of total LDL fatty acids (p < 0.01). Both linoleic and arachidonic acids turned out to be negatively correlated with the lag phase and positively with the propagation phase (p < 0.01). The concentration of LDL alpha-tocopherol was similar in the two groups. Therefore, type IIa patients have a greater susceptibility to LDL oxidation than control subjects. This may be due to a relative higher concentration of linoleic and arachidonic acids in LDL derived from patients with familial hypercholesterolemia.
Cominacini
L
L
Istituto di Semeiotica e Nefrologia Medica, Università di Verona, Italy.
Pastorino
A M
AM
Garbin
U
U
Campagnola
M
M
de Santis
A
A
Davoli
A
A
Faccini
G
G
Bertozzo
L
L
Pasini
F
F
Pasini
A F
AF
D000328:Adult; D000886:Anthropometry; D000975:Antioxidants / Q000378:metabolism; D016718:Arachidonic Acid / Q000097:blood / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood / Q000378:metabolism; D003300:Copper / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000097:blood / Q000378:metabolism; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000097:blood / Q000378:metabolism; D015227:Lipid Peroxidation; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D013997:Time Factors; D014810:Vitamin E / Q000097:blood / Q000378:metabolism
D000975:Antioxidants; D008078:Cholesterol, LDL; D005231:Fatty Acids, Unsaturated; D008041:Linoleic Acids; D008077:Lipoproteins, LDL; D014810:Vitamin E; D016718:Arachidonic Acid; D003300:Copper; D019787:Linoleic Acid